Searchable abstracts of presentations at key conferences in endocrinology

ea0032p1014 | Thyroid (non-cancer) | ECE2013

Biochemical testing on wide indication to detect overt hypothyroidism is justified: a population-based case–control study in patients newly diagnosed with overt autoimmune hypothyroidism

Carle Allan , Pedersen Inge Bulow , Knudsen Nils , Ovesen Lars , Rasmussen Lone Banke , Jorgensen Torben , Perrild Hans , Laurberg Peter

Objectives: Hypothyroid patients report a diversity of symptoms at disease presentation. We studied how useful symptoms are to predict hypothyroidism, and if this may vary between subgroups of patients.Methods: Patients newly diagnosed with overt autoimmune hypothyroidism (n=140) were prospectively identified in a population by linkage to diagnostic laboratory databases, and we concomitantly enrolled individually sex and age-region matched contr...

ea0029oc1.6 | Pituitary Clinical I | ICEECE2012

Normal weight adult patients with Prader–Willi syndrome are not protected from insulin resistance during treatment with GH: results from a 12 month prospective study

Jorgensen A. , Ueland T. , Sode-Carlsen R. , Schreiner T. , Rabben K. , Farholt S. , Hoybye C. , Christiansen J. , Bollerslev J.

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...

ea0022p229 | Clinical case reports and clinical practice | ECE2010

Dose of growth hormone (GH) and not IGFI level at treatment start influences treatment outcome in GH deficient adults (GHDA): Data from the NordiNet International Outcome Study (IOS)

Jorgensen Jens Otto L , Weber Matthias M , Hoybye Charlotte , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

ea0022p264 | Developmental endocrinology | ECE2010

Baseline characteristics and serum IGF1 levels in GH deficient (GHD) patients treated in the transition phase from adolescence into adulthood: data from the NordiNet International Outcome Study (IOS)

Weber Matthias M , Blankenstein Oliver , Jorgensen Jens Otto L , Pedersen Birgitte T , Rakov Viatcheslav , Christiansen Jens Sandahl

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...

ea0022p639 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Sub-acute tumour debulking with somatostatin analogues in newly diagnosed acromegaly due to macroadenomas

Olarescu Cristina , Husby Oystein , Heck Ansgar , Ringstad Geir , Ramm-Pettersen Jon Terje , Jorgensen Anders Palmstrom , Bollerslev Jens

Background: Surgery is accepted as first line treatment of somatotroph macroadenomas with involvement of the optic chiasm. However, during recent years somatostatin analogues (SA) have increasingly been used as primary treatment improving ultimate cure rate, as SA’s have anti-proliferative effects in most tumours. We demonstrate here positive effect of subacute/acute SA treatment on tumour shrinkage and chiasm decompression in two recently diagnosed acromegalic patients.<...

ea0016p740 | Thyroid | ECE2008

Serum ghrelin levels are increased in hypothyroid patient and become normalized after L-thyroxin treatment

Gjedde Signe , Vestergaard Esben Thyssen , Gormsen Lars Christian , Riis Anne Lene , Rungby Jorgen , Moller Niels , Weeke Jorgen , Jorgensen Jens Otto

Context: An interaction between gut-derived ghrelin, which is implicated in the regulation of short- and long-term energy balance, and thyroid function has previously been reported in patients with hyperthyroidism, in whom ghrelin levels are reversibly suppressed. In the present study, we measured total serum ghrelin levels and pertinent metabolic indices in hypothyroid patients before end after L-thyroxin replacement.Patients and methods:...

ea0099oc1.6 | Oral Communications 1: Reproductive and Developmental Endocrinology | ECE2024

Sertoli cell function and the dose of denosumab is critical for the response to RANKL inhibition in human testis cultures

Andreassen Christine Hjorth , Krarup Knudsen Nadia , Erik Nielsen John , Kafai Yahyavi Sam , Holt Rune , Jorgensen Anne , Blomberg Jensen Martin

Currently, no treatment options exist to improve semen quality for the majority of infertile men, but it is well known that the interaction between Sertoli- and germ cells is essential to ensure complete spermatogenesis. A recent study suggested that denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL) signaling, may decrease germ cell apoptosis in human ex vivo testis cultures and stimulate sperm production in some infertile men. Her...

ea0099p361 | Reproductive and Developmental Endocrinology | ECE2024

Prenatal testosterone exposure and offspring body composition at 7 years-of-age. odense child cohort

Palm Camilla , Glintborg Dorte , Grontved Anders , Jensen Dorte , Hansen Freja , Jorgensen Jan , Christesen Henrik , Jensen Tina , Andersen Marianne

Background: Maternal free testosterone (FT) increases during 3rd trimester pregnancy and FT levels are higher in women with polycystic ovary syndrome (PCOS) compared to controls. Fetal exposure to maternal FT during 3rd trimester was associated with lower weight, length and shorter abdominal circumference at birth, in boys. Furthermore, lower birth weight has been related to higher abdominal fat mass in young children.Aim: To examine associations between...

ea0081p144 | Pituitary and Neuroendocrinology | ECE2022

Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in active acromegaly

Maria Falch Camilla , Arlien-Soborg Mai C. , Dal Jakob , Sundaram Arvind , Michelsen Annika E. , Ueland Thor , Olsen Linn G. , Heck Ansgar , Bollerslev Jens , Jorgensen Jens Otto , Olarescu Cristina

Objective: Patients with acromegaly present increased insulin resistance despite reduced adipose tissue (AT) mass. Growth hormone (GH) stimulates lipolysis, but the role of AT as a metabolic factor in patients with acromegaly is still uncertain. Moreover, there is a need for better biomarkers of disease activity in acromegaly.Methods: RNA-sequencing was performed on paired subcutaneous AT (SAT) biopsies from patients (n=6) with active acromegaly...

ea0081p657 | Pituitary and Neuroendocrinology | ECE2022

Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment

C. Arlien-Soborg Mai , Alle Madsen Michael , Dal Jakob , Krusenstjerna-Hafstrom Thomas , Ringgaard Steffen , Skou Nickolaj , Lyng Hogild Morten , Otto Jorgensen Jens

Background: Insulin resistance as part of the metabolic syndrome is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation but how this associates with insulin resistance in patients with GH disorders is not well established.Aim: To study body composition, ectopic lipid deposition and insulin sensitivity in acromegaly and adult GH-deficiency before and after treatment.Subjects...